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ABSTRACT
Background: Congenital limb malformations (CLMs) are
common and present to a variety of specialties, notably
plastic and orthopaedic surgeons, and clinical geneticists.
The authors aimed to characterise causative mutations in
an unselected cohort of patients with CLMs requiring
reconstructive surgery.
Methods: 202 patients presenting with CLM were
recruited. The authors obtained G-banded karyotypes and
screened EN1, GLI3, HAND2, HOXD13, ROR2, SALL1,
SALL4, ZRS of SHH, SPRY4, TBX5, TWIST1 and WNT7A for
point mutations using denaturing high performance liquid
chromatography (DHPLC) and direct sequencing. Multiplex
ligation dependent probe amplification (MLPA) kits were
developed and used to measure copy number in GLI3,
HOXD13, ROR2, SALL1, SALL4, TBX5 and the ZRS of SHH.
Results: Within the cohort, causative genetic alterations
were identified in 23 patients (11%): mutations in GLI3
(n=5), HOXD13 (n=5), the ZRS of SHH (n=4), and
chromosome abnormalities (n=4) were the most
common lesions found. Clinical features that predicted the
discovery of a genetic cause included a bilateral
malformation, positive family history, and having increas-
ing numbers of limbs affected (all p,0.01). Additionally,
specific patterns of malformation predicted mutations in
specific genes.
Conclusions: Based on higher mutation prevalence the
authors propose that GLI3, HOXD13 and the ZRS of SHH
should be prioritised for introduction into molecular
genetic testing programmes for CLM. The authors have
developed simple criteria that can refine the selection of
patients by surgeons for referral to clinical geneticists.
The cohort also represents an excellent resource to test
for mutations in novel candidate genes.
Congenital limb malformations (CLMs) affect
approximately 1 in 500 live births
1 and usually
require surgical intervention to improve functional
and aesthetic outcome. CLMs are very diverse in
their epidemiology, aetiology and anatomy. In
around half of cases, CLMs occur bilaterally, and
in unilateral CLM the right and left sides are
affected with approximately equal frequency. Up
to 18% of children with a CLM die before the age
of 6 years, usually because of associated malforma-
tions.
1 Major causes of CLM include intrauterine
disruptions (for example, caused by fetal haemor-
rhage, hypovolaemia or teratogenesis) and genetic
abnormalities (chromosome abnormalities and
single gene mutations). Major anatomical cate-
gories of CLM include limb hypoplasia reduction
defects, brachydactylies, and the polydactyly–
syndactyly–triphalangism group.
2
Previous investigations into the genetics of
human CLM have taken two approaches. First,
positional candidate methods have been used to
identify mutated genes in affected families follow-
ing linkage analysis, or in individuals harbouring
chromosome abnormalities.
34 Second, genetic
mutations causing CLM have been identified in
model organisms such as the mouse, and the
orthologous gene in humans has been screened for
mutations in patients with a similar phenotype.
5
Although these approaches have yielded many
important gene discoveries, they also have inherent
methodological problems. A suitable pedigree
structure is required for linkage analysis, meaning
that only a small proportion of patients will be
suitable for study; similarly, chromosome abnorm-
alities are a relatively uncommon cause of CLM.
The model organism/candidate gene approach
assumes a correlation between the phenotypes
present in the model organism and in the human:
this is not always the case. For example, hetero-
zygous mutations in the mouse gene Alx4 cause
polydactyly, whereas the limbs are normal when
the exactly equivalent mutation occurs in the
human orthologue.
67
In this study we took a different approach to the
genetic analysis of CLM. We recruited from a
paediatric hand surgery clinic a large cohort of
unselected patients with CLM, who underwent
surgery; we then undertook mutation analysis of
selected genes in the entire cohort, regardless of
phenotype. This approach has three potential
advantages. First, it makes no prior assumption
about which patients will harbour mutations in
which gene, allowing the discovery of novel
phenotypes associated with mutations in genes
already known to cause human CLM. Second, it
allows unbiased estimation of the relative con-
tribution of mutations in different genes to the
total burden of human CLM; this has not been
reported previously. Third, the cohort constitutes a
large panel to search for mutations in novel
candidate genes as they are discovered in model
organisms, without assuming any specific pheno-
typic correlation in the pattern of CLM.
For this study we chose candidate genes falling
into two broad groups. First, we selected genes in
which mutations causing human CLMs had been
described previously: GLI3, HOXD13, ROR2, SALL1,
SALL4, ZRS of SHH,a n dTBX5.
3–5 8–13 Here we aimed
to quantify their contribution to human CLM and,
potentially, to extend the phenotypic spectrum of
mutations. Second, we selected genes either known
to play critical roles in limb development or mutated
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human orthologue causing isolated CLM had not atthe time been
reported: EN1, HAND2, SPRY4, TWIST1,a n dWNT7A.
14–17 Here,
the aim was to describe novel mutations and therefore provide
further insight into the molecular genetics of human limb
formation and CLM.
In this report, we describe this genetic analysis of the cohort.
The results were also used to identify clinical characteristics
that predict a genetic aetiology, and thereby define referral
criteria for patients to clinical genetics services.
METHODS
Subjects
Approval for the work was obtained from the Oxford Research
Ethics Committee C (C99.181: Molecular basis of congenital
limb abnormalities). Consent was requested from all parents/
guardians of patients presenting between 1999 and 2006 to the
Department of Plastic and Reconstructive Surgery, Oxford,
with a congenital CLM requiring reconstructive surgery. At
operation, 3–10 ml of venous blood was collected, which was
used for routine karyotype analysis and isolation of genomic
DNA using phenol/chloroform extraction. A database contain-
ing detailed phenotypic information on each patient recruited to
the study was created, and the clinical notes of all patients were
individually reviewed.
The family history was obtained by the surgeon in clinic. For
statistical comparisons, we utilised two definitions of a positive
family history of CLM: (1) having any relative affected with an
identical or very similar CLM; and (2) the more strict definition
of having an affected first degree relative.
Mutation screening
Screening for point mutations was undertaken by WAVE
denaturing high performance liquid chromatography (DHPLC)
(Transgenomic, Omaha, Nebraska, USA), followed by direct
sequencing of abnormally eluting fragments as previously
described.
18 All primer sequences and reaction conditions are
available on request.
19 Owing both to continuing recruitment
while molecular analysis was ongoing, and mutations being
discovered in some patients, each gene was screened in different
numbers of patients as follows: EN1, 187; GLI3, 198; HAND2,
174; HOXD13, 175; ROR2, 139; SALL1, 197; SALL4, 183; ZRS of
SHH, 187; SPRY4, 149; TBX5, 160; TWIST1, 188; WNT7A, 187.
In collaboration with MRC-Holland (Amsterdam, The
Netherlands), we designed
20 multiplex ligation dependent probe
amplification (MLPA) probe sets to test for deletions of all exons
of GLI3, HOXD13, ROR2, TBX5, SALL1 and SALL4 (MLPA probe
sets P179 and P180, MRC-Holland). Details of the probe
sequence at the ligation site are provided in supplemental tables
S1 and S2. The probe sets P179 and P180 were used to screen
194 and 198 subjects, respectively. A subset of patients (n=26),
chosen because they had bilateral syndactyly and/or polydac-
tyly, was screened for abnormal dosage of the ZRS of SHH using
a previously described MLPA probe mix.
21 Statistical compar-
isons between dichotomous variables were made using Fisher’s
exact test.
RESULTS
Genetic abnormalities identified in the cohort
In total, 202 patients were recruited to the study; their clinical
features are summarised in table 1. Of these, 98 (49%) had more
than one limb affected; 51 (25%) had a family history of
CLM including 42 (21%) with an affected first degree relative.
Twenty-sevenpatients(13%)hadnon-limbmalformations,which
in 13 (6%) constituted a recognised syndrome or association. The
most common CLM was polydactyly (56% of cases), with
postaxial being about twice as common as preaxial polydactyly.
Syndactyly, either isolated or combined with polydactyly, was the
next most common malformation (21%), followed by longitudinal
dysplasia (9%) and symbrachydactyly (6%).
The cohort includes five patients in whom a cytogenetic or
molecular diagnosis (three chromosome abnormalities, and
single mutations in ESCO2 and SALL1) was made indepen-
dently as a result of routine clinical care. In a further 18 cases, a
new cytogenetic or molecular diagnosis was obtained through
our research protocol, giving a total of 23 subjects (11% of the
total) with a proven genetic lesion accounting for their
malformation. Several of the mutations in GLI3, HOXD13,
SALL1, and ZRS of SHH discovered in this cohort have been
reported in previous publications
18 21–23; selected data for
unpublished mutations are shown in supplemental fig S1.
The molecular/cytogenetic and clinical details of this ‘‘genetic
diagnosis’’ cohort are summarised in table 2. Of the 19
molecular alterations listed in table 2, 13 were considered
obviously pathogenic because they represented deletions,
duplications or nonsense mutations involving known disease
genes. Of the remaining nucleotide substitutions, supporting
Table 1 Clinical characteristics of the cohort
Phenotypic characteristic Number*
% Mutation
positive
% Genetic
component{
Total 202 11 32
Number of limbs affected
42 0 3 0 5 5
3 6 33 50
27 2 1 7 4 4
1 104 2 17
Bilateral malformation 97 22 47
Positive family history 51 24 100
Syndrome or association 13 38 54
Other non-limb malformations not
classified into a syndrome
14 36 43
Polydactyly
Postaxial 75 5 39
Preaxial 34 26 38
Pre- and postaxial 4 50 50
Triphalangeal thumb 5 80 80
Syndactyly 31 16 32
Polysyndactyly 12 33 42
Longitudinal dysplasia
Radial 8 25 63
Ulnar 3 0 0
Central 7 0 14
Symbrachydactyly 13 0 0
Brachydactyly 1 0 100
Clinodactyly 8 13 25
Camptodactyly 4 25 25
Hypoplastic digits
Thumb 4 0 0
Other digits 4 0 0
Trigger thumb 5 0 0
Constriction ring syndrome 3 0 0
Other 10 30 30
*Totals do not add up to 202 as 24 children had multiple limb malformations which
were included in between two and five categories.
{Genetic component consists of individuals with either a cytogenetic or molecularly
proven diagnosis, a positive family history of congenital limb malformation (CLM), or a
known genetically determined syndrome (see section: Estimation of the overall genetic
contribution to CLM).
Original article
J Med Genet 2009;46:730–735. doi:10.1136/jmg.2009.066027 731evidence for pathogenicity of the 940A.C (I314L) substitution
encoded by HOXD13 and the 295T.C substitution in the ZRS
of SHH is discussed elsewhere.
18 21 The 266T.A mutation in
TBX5, encoding V89E, affects a conserved residue in the DNA
binding T-box and was not identified in 265 controls.
The most common causative genetic alterations that we
identified in our CLM cohort were heterozygous mutations in
GLI3 (n=5), HOXD13 (n=5), ZRS of SHH (n=4), and
miscellaneous microscopically visible chromosome abnormalities
(n=4). More unusual were mutations in SALL1 (n=2), SALL4
(n=1) and TBX5 (n=1). We did not find any pathogenic
mutations in the remaining genes screened, including all those
genes not yet associated with defined human CLM syndromes
(EN1, HAND2, SPRY4 and TWIST1), as well as ROR2 and
WNT7A. After this study was initiated, recessive mutations of
WNT7A were reported in Al-Awadi/Raas-Rothschild/Schinzel
phocomelia and Fuhrmann syndromes (MIM 228930)
24;h o w e v e r ,
our cohort did not include any individuals with these disorders.
In addition to the above pathogenic mutations, we identified
33 additional non-synonymous variants that were considered
either non-pathogenic or where the evidence was inconclusive,
as itemised in supplemental table S3. A further 80 synonymous
and non-coding variants were identified: where these were not
known single nucleotide polymorphisms (SNPs), we checked
the possibility that they created cryptic splice sites using a
neural network splice site prediction program (supplemental
tables S4–S6). Our sample size is too small to exclude the
possibility that some of these variants act as susceptibility
alleles for particular CLMs.
Factors predicting the discovery of a genetic cause for the CLM
We examined both the general clinical features of the 23
subjects in the genetic diagnosis group and the specific clinical
features that might have led to the correct genetic diagnosis
independently of our research protocol. Twenty-one of the 23
patients had a bilateral malformation (96%), compared to 76/
179 (42%) without a confirmed genetic diagnosis (p,5610
26).
There was a positive family history of CLM in 12/23 (52%) with
a genetic diagnosis, compared to 39/179 (22%) without
(p=0.004). Using the stricter criterion of having a first degree
relative affected with an identical or very similar malformation,
12/23 (52%) with a genetic diagnosis had a positive family
history of CLM, compared to 30/179 (17%) without
(p=0.0004). Having increasing numbers of limbs affected also
predicted the discovery of a molecular genetic cause for the
malformation: 6/23 (26%) of those with a molecular genetic
diagnosis had all four limbs affected, compared to 12/179 (7%)
without (p=0.008), and 21/23 (91%) of patients with a
molecular genetic diagnosis had more than one limb affected,
compared to 77/179 (43%) without (p=6610
26).
Specificpatternsof malformationwere alsoassociatedwith the
discovery of a mutation. Four out of five patients (80%) with
mutations in GLI3 had a combination of bilateral preaxial
polydactyly of the feet and a hand malformation. In contrast,
only two other patients had preaxial polydactyly of the foot, in
both cases it was unilateral, and in only one case was it associated
with a hand malformation. Thus, the presence of bilateral
preaxial polydactyly of the feet, especially if combined with a
handmalformation,isstronglyassociatedwithmutationinGLI3.
Two other examples of specific patterns of malformation are
provided by triphalangeal thumb and ring finger duplication. All
three patients with bilateral triphalangeal thumb harboured an
identical substitution in the ZRS of SHH.
21 Only two other
patients in the cohort had triphalangeal thumb, and in neither
case was the malformation bilateral; one patient had unilateral
triphalangeal thumb associated with ipsilateral preaxial poly-
dactyly and a mutation in SALL1,
22 the other had triphalangeal
thumb associated with tetralogy of Fallot, and no identified
mutation. Thus, the presence of triphalangeal thumbs (espe-
cially if bilateral) is strongly suggestive of a mutation in the ZRS
of SHH. Both patients with partial duplication of the ring finger
had HOXD13 mutations, but this criterion would miss three of
the HOXD13 mutations. Broadening the diagnostic criterion to
syndactyly of the third webspace of the hand would yield two
additional cases with HOXD13 mutation, at the expense of
including a further 18 subjects negative for HOXD13 mutation.
Estimation of the overall genetic contribution to CLM
In addition to the 23 probands in whom a genetic diagnosis was
made, 39 other patients (25 with isolated postaxial polydactyly)
had a family history of similar CLM, suggesting a contribution by
either single gene mutations or polygenic variants. Two further
sporadic patients had clinical diagnoses of Fanconi anaemia but
did nothave a specificmutationidentified. Therefore,a minimum
of 64/202 (32%) of patients with a CLM requiring reconstructive
surgery have a genetic contribution to their malformation.
DISCUSSION
To our knowledge, this study is the first to screen system-
atically for mutations in an unselected cohort of individuals
with CLMs requiring reconstructive surgery. We discovered
mutations in GLI3, HOXD13, SALL1, SALL4, the ZRS of SHH
and TBX5 in 17 patients, karyotyping revealed a pathological
rearrangement in a single patient, and the clinical genetics
service independently obtained a cytogenetic or molecular
genetic diagnosis in five patients, making a total of 23/202
(11%) patients in the cohort with a defined genetic diagnosis.
It may appear surprising that only 5/23 (22%) of these genetic
diagnoses were achieved through routine clinical genetics
services. This appears to reflect two factors. First, despite
sometimes extensive family histories, most patients with
genetic diagnoses (16/23) had not been referred by their medical
carers for genetic counselling. It is possible that the relative lack
of availability of genetic testing services for CLM, and a
subjective lack of concern on the part of some parents about the
nature and genetic implications of the CLM, may have
contributed to this under-referral. Second, in the two additional
cases previously referred to clinical geneticists, the (retro-
spectively correct) clinical diagnosis had not been confirmed
molecularly. In one instance (OX2084, TBX5 mutation) a
tentative diagnosis of Holt–Oram syndrome (MIM 142900)
had been made, but an electrocardiogram (ECG) and echocar-
diogram were normal, and genetic testing was not arranged. In
another (OX3424, ZRS triplication), the correct clinical diag-
nosis of syndactyly type IV (Haas) (MIM 186200) was
suggested, but the role of rearrangements of the ZRS of SHH
in the aetiology of this disorder
25 was not known at the time. In
none of the probands with GLI3 mutations had the diagnosis of
Greig cephalopolysyndactyly (GCPS, MIM 175700) been sug-
gested previously, even though this was clinically apparent
retrospectively in four of the five subjects.
It is interesting to analyse the extent to which the
universal screening approach that we adopted in this study
fulfilled the three anticipated advantages that we identified
in the introduction. Certainly we could estimate, in an
unbiased fashion, the relative mutation frequencies of genes
for which mutations have a well established role in CLM.
Original article
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commonly mutated in CLM; those genes most frequently
mutated (GLI3 and HOXD13, five cases each) demonstrated
an overall prevalence of only 2.5–2.8%. Although the
difference between identifying one and five cases in this
series is not statistically significant, these data do support
prioritisation of the introduction of testing for GLI3,
HOXD13 and the ZRS of SHH in clinical diagnostic services,
on the basis that multiple mutations were identified: indeed,
testing of the first two of these genes is now available
through the Genetics Laboratories in Oxford (http://www.
oxfordradcliffe.nhs.uk/forpatients/departments/labs/geneticslab/
documents/diseaseservices.pdf (accessed 7 September 2009)). In
many cases, careful evaluation of the phenotype would substan-
tially enhance the specificity of genetic testing. For example, if the
presence of bilateral preaxial polydactyly of the feet was made an
essential criterion for testing GLI3, this would result in a
sensitivity of 80% (four of five GLI3 mutations identified) and a
positive predictive value (PPV) of 100% (four of four individuals
with specified phenotype have a GLI3 mutation). A high
sensitivity and PPV could also be achieved for the association of
ZRS mutations and triphalangeal thumb (sensitivity 75%, PPV
60%). Mutations of HOXD13 would be more difficult to pick out:
although synpolydactyly 1 (SPD1; MIM 186000) is the classic
phenotypeassociatedwithpolyalaninetractexpansionmutations
(such as that identified in case OX2137), different molecular
categories of HOXD13 mutation present with variant phenotypes
as illustrated by the other cases discovered in our series (table 2
and discussed below). Use of ring finger duplication or third web
space syndactyly as the diagnostic criterion for HOXD13
mutation in our series would have had good sensitivity (80%)
but relatively poor PPV (18%).
A further benefit from our screening strategy is that we
identified two new associations between CLMs and particular
mutant alleles, both of which we have reported elsewhere: we
found a novel HOXD13 mutation encoding I314 L in two
independent families segregating a specific disorder with
features combining SPD1 and brachydactyly type E (MIM
113300),
18 and a specific alteration of the ZRS of SHH, 295 T.
C, as a common cause (three independent cases) of triphalangeal
thumb, representing the mild end of a phenotypic spectrum
including preaxial polydactyly type II (MIM 174500).
21 In
addition we found mutations or cytogenetic abnormalities in a
further five cases that were not readily predictable from the
phenotype (footnote  to table 2). Three of these (isolated
postaxial polydactyly and GLI3 mutation, unilateral preaxial
polydactyly with triphalangeal thumb and SALL1 mutation,
limb reduction defect and t(2;18) chromosome translocation)
have been reported in detail elsewhere.
22 26 The other two cases
were preaxial polydactyly of the hands in a child with
dup(6)(p22.3p23); and postaxial polydactyly of one foot with
marked bilateral clinodactyly of the little fingers, associated
with a heterozygous nonsense mutation (R319X) in HOXD13
(supplemental fig S1D). Although we were not successful in
identifying a novel role for any of the more speculative
candidate human genes in isolated CLM, our DNA panel
provides a resource for further genetic studies as new candidates
are identified.
As part of this project we designed new MLPA kits for the
identification of deletions in the GLI3, HOXD13, ROR2, SALL1,
SALL4 and TBX5 genes. The diagnostic yield from MLPA
analysis of the cohort was low, with only a single partial GLI3
deletion being identified; however, the probe sets have subse-
quently been implemented in diagnostic laboratories, where
additional deletions or duplications in GLI3, HOXD13, and
SALL1 have been identified in patients previously without a
molecular diagnosis (M Oldridge, G Cross, personal commu-
nication, 2008).
Clearly the list of known CLM genes included in our screen
was not exhaustive
27; we focused on genes associated with
variable CLM phenotypes in the better recognised, mostly
dominantly inherited syndromes. Indeed some members of the
cohort had clinical diagnoses (for example, Fanconi anaemia,
ectrodactyly, and brachydactyly type C), that are associated
with known genetic changes that we did not investigate, as this
was outside the purpose of the study. These subjects were all
included in the ‘‘genetic component’’ group in table 1. The
minimum figure of 32% of patients from the cohort having a
genetic aetiology for their malformation represents the first
estimate of the genetic contribution to CLM. Previous
epidemiological studies have focused on the incidence and type
of malformation to aid in medical workforce planning,
1 have
focused on CLM diagnosed prenatally,
28 or have looked for an
association between environmental, maternal or teratogenic
factors and specific types of CLM.
29 Clinical features that
predicted the discovery of a genetic cause for the CLM were the
presence of a bilateral malformation, a positive family history of
CLM, and an increasing number of limbs being affected.
Furthermore, specific patterns of CLM predicted a genetic
aetiology. Based on these data, we propose some simple
guidelines (table 3) that should trigger the referral of patients
by surgeons to clinical genetics services for diagnosis and
investigation. All the suggested criteria at least double the
likelihood of a specific molecular or cytogenetic abnormality
being identified.
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